PARGP1, a specific enhancer RNA associated with biochemical recurrence of prostate cancer

References

• Abdollah F, Dalela D, Sood A, Keeley J, Alanee S, Briganti A, Montorsi F, Peabody JO, Menon M. 2018. Impact of adjuvant radiotherapy in node-positive prostate cancer patients: the importance of patient selection. Eur Urol. 74(3):253–256.
   Web of Science ®Google Scholar
• Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, Chen Y, Zhao X, Schmidl C, Suzuki T, Ntini E. 2014. An atlas of active enhancers across human cell types and tissues. Nature. 507(7493):455–461.
   PubMed Web of Science ®Google Scholar
• Bleyer A, Spreafico F, Barr R. 2020. Prostate cancer in young men: an emerging young adult and older adolescent challenge. Cancer. 126(1):46–57.
   PubMed Web of Science ®Google Scholar
• Bose DA, Berger SL. 2017. eRNA binding produces tailored CBP activity profiles to regulate gene expression. RNA Biol. 14(12):1655–1659.
   PubMed Web of Science ®Google Scholar
• Corradin O, Saiakhova A, Akhtar-Zaidi B, Myeroff L, Willis J, Cowper-Sal R, Lupien M, Markowitz S, Scacheri PC. 2014. Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. Genome Res. 24(1):1–13.
   PubMed Web of Science ®Google Scholar
• Eapen RS, Nzenza TC, Murphy DG, Hofman MS, Cooperberg M, Lawrentschuk N. 2019. PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics. World J Urol. 37(7):1255–1261.
   PubMed Web of Science ®Google Scholar
• Eskra JN, Rabizadeh D, Pavlovich CP, Catalona WJ, Luo J. 2019. Approaches to urinary detection of prostate cancer. Prostate Cancer Prostatic Dis. 22(3):362–381.
   Web of Science ®Google Scholar
• Gu X, Wang L, Boldrup L, Coates PJ, Fahraeus R, Sgaramella N, Wilms T, Nylander K. 2019. AP001056.1, a prognosis-related enhancer RNA in squamous cell carcinoma of the head and neck. Cancers (Basel). 11(3):347.
   Web of Science ®Google Scholar
• Kim M, Osborne NR, Zeng W, Donaghy H, McKinnon K, Jackson DC, Cunningham AL. 2012. Herpes simplex virus antigens directly activate NK cells via TLR2, thus facilitating their presentation to CD4T lymphocytes. J Immunol. 188(9):4158–4170.
   Web of Science ®Google Scholar
• Kim TK, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, Harmin DA, Laptewicz M, Barbara-Haley K, Kuersten S, Markenscoff-Papadimitriou E. 2010. Widespread transcription at neuronal activity-regulated enhancers. Nature. 465(7295):182–187.
   PubMed Web of Science ®Google Scholar
• Léveillé N, Melo CA, Agami R. 2015. Enhancer-associated RNAs as therapeutic targets. Expert Opin Biol Ther. 15(5):723–734.
   PubMed Web of Science ®Google Scholar
• Li W, Notani D, Rosenfeld MG. 2016. Enhancers as non-coding RNA transcription units: recent insights and future perspectives. Nat Rev Genet. 17(4):207–223.
   PubMed Web of Science ®Google Scholar
• Liu X, Yu C, Bi Y, Zhang ZJ. 2019. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. Public Health. 172:70–80.
   PubMed Web of Science ®Google Scholar
• Mikhaylichenko O, Bondarenko V, Harnett D, Schor IE, Males M, Viales RR, Furlong EE. 2018. The degree of enhancer or promoter activity is reflected by the levels and directionality of eRNA transcription. Genes Dev. 32(1):42–57.
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. 2019. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69(5):363–385.
   PubMed Web of Science ®Google Scholar
• Nguyen-Nielsen M, Borre M. 2016. Diagnostic and therapeutic strategies for prostate cancer. Semin Nucl Med. 46(6):484–490.
   Web of Science ®Google Scholar
• Pang C, Guan Y, Li H, Chen W, Zhu G. 2016. Urologic cancer in China. Jpn J Clin Oncol. 46(6):497–501.
   PubMed Web of Science ®Google Scholar
• Puc J, Kozbial P, Li W, Tan Y, Liu Z, Suter T, Ohgi KA, Zhang J, Aggarwal AK, Rosenfeld MG. 2015. Ligand-dependent enhancer activation regulated by topoisomerase-I activity. Cell. 160(3):367–380.
   PubMed Web of Science ®Google Scholar
• Samudio I, Hofs E, Cho B, Li M, Bolduc K, Bu L, Liu G, Lam V, Rennie P, Jia W, Elisia I. 2019. UV Light-inactivated HSV-1 stimulates natural killer cell-induced killing of prostate cancer cells. J Immunother. 42(5):162–174.
   Web of Science ®Google Scholar
• Sartor O. 2020. Why is prostate cancer incidence rising in young men? Cancer. 126(1):17–18.
   Web of Science ®Google Scholar
• Sebesta EM, Anderson CB. 2017. The surgical management of prostate cancer. Semin Oncol. 44(5):347–357.
   PubMed Web of Science ®Google Scholar
• Taneja S, MacGregor J, Markus S, Ha S, Mohr I. 2001. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci USA. 98(15):8804–8808.
   PubMed Web of Science ®Google Scholar
• Vogel K, Thomann S, Vogel B, Schuster P, Schmidt B. 2014. Both plasmacytoid dendritic cells and monocytes stimulate natural killer cells early during human herpes simplex virus type 1 infections. Immunology. 143(4):588–600.
   Web of Science ®Google Scholar
• Vučićević D, Corradin O, Ntini E, Scacheri PC, Ørom UA. 2015. Long ncRNA expression associates with tissue-specific enhancers. Cell Cycle. 14(2):253–260.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lee JH, Ruan H, Ye Y, Krakowiak J, Hu Q, Xiang Y, Gong J, Zhou B, Wang L, Lin C. 2019. Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer. Nat Commun. 10(1):4562.
   PubMedGoogle Scholar
• Zhao Y, Wang L, Ren S, Wang L, Blackburn PR, McNulty MS, Gao X, Qiao M, Vessella RL, Kohli M, Zhang J. 2016. Activation of P-TEFb by androgen receptor-regulated enhancer RNAs in castration-resistant prostate cancer. Cell Rep. 15(3):599–610.
   PubMed Web of Science ®Google Scholar